TNFRSF8 and neoplasm: Brentuximab vedotin (BV) is an antibody–drug conjugate that targets CD30 on the surface of the malignant Reed–Sternberg cell; the antibody is linked to a microtubule inhibitor called monomethyl auristatin E. The binding of BV to CD30 on the tumor cell membrane triggers a cascade of events that ultimately results in apoptotic death of the CD30-expressing cell.